Anzeige
Mehr »
Login
Mittwoch, 27.01.2021 Börsentäglich über 12.000 News von 653 internationalen Medien
Letzte große Gelegenheit bei einer ganz großen Kurswette...
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 866197 ISIN: US2358511028 Ticker-Symbol: DAP 
Tradegate
26.01.21
21:55 Uhr
192,56 Euro
-3,58
-1,83 %
1-Jahres-Chart
DANAHER CORPORATION Chart 1 Jahr
5-Tage-Chart
DANAHER CORPORATION 5-Tage-Chart
RealtimeGeldBriefZeit
192,14193,1226.01.
191,76192,9826.01.
PR Newswire
482 Leser
Artikel bewerten:
(2)

Cepheid Receives CE-IVD Registration for SARS-CoV-2, Flu A, Flu B and RSV Combination Test

Challenged by Similar Clinical Presentations, Accurate Detection & Differentiation of all 4 Viruses is Critical for Clinicians This Flu Season

SUNNYVALE, Calif., Nov. 24, 2020 /PRNewswire/ -- Cepheid today announced the CE-IVD marking of Xpert Xpress SARS-CoV-2/Flu/RSV, a rapid molecular diagnostic test for qualitative detection of the viruses causing COVID-19, Flu A, Flu B, and RSV infections from a single patient sample. The test, which received Emergency Use Authorization from the U.S. Food & Drug Administration in September 2020, is now available in the European Union and other markets that recognize CE-IVD marking. The four-in-one test is designed for use on any of Cepheid's almost 30,000 GeneXpert Systems placed worldwide, with results delivered in approximately 36 minutes.

"Things may get complicated this respiratory season as clinicians encounter a range of viral infections with symptoms overlapping with COVID-19, including Flu A, Flu B, and respiratory syncytial virus," said Dr. David Persing, MD, Ph.D., Chief Medical and Technology Officer at Cepheid. "The ability to run a single, highly sensitive test that detects all four viruses in a syndromic panel provides actionable results and helps to alleviate pressure on our healthcare system."

Cepheid's previously announced capacity expansion program, supported by parent company Danaher Corporation, was designed in part to address anticipated demand for Xpert Xpress SARS-CoV-2/Flu/RSV. Cepheid expects the first impact of the program in the fourth quarter of 2020 with additional capacity ramping through 2021.

"The dramatic impact of SARS-CoV-2 has been felt by us all, and we understand that a reliable supply of SARS-CoV-2 tests is critical to the communities our healthcare institutions serve - for the coming Flu season and beyond," said Cepheid President Warren Kocmond. "Another goal of the capacity expansion program is to ensure supply continuity of not only our 4-Plex combination test for SARS-CoV-2, Flu A&B and RSV, but the entire portfolio of critical tests Cepheid supplies - including tests for tuberculosis, MRSA, C. difficile, CT/NG, Strep A, and many more."

Visit www.cepheid.com/en/about/SARS-CoV-2-Test-Development-Information for more information, videos, package inserts and more.

GeneXpert System - Reference Lab Quality Tests Anywhere They Are Needed

The GeneXpert System was built for simple, reference lab quality PCR testing - on location at medical centers and hospitals or closer to patient in health clinics and nursing homes. At the core of every GeneXpert System is the module (or testing bay) where a test cartridge is loaded onto the machine. Our GeneXpert Systems are configured with a varying number of modules, or test bays, to meet the volume requirements of any setting. Smaller GeneXpert Systems are configured with 2 or 4 modules - meaning up to four different tests can be run at one time. Our largest GeneXpert System is configured with up to 80 modules - meaning as many as 80 tests can operate independently at any given time with a capacity of about 2,000 tests per day.*

About Cepheid
Based in Sunnyvale, Calif., Cepheid is a leading molecular diagnostics company that is an operating company within Danaher Corporation's (NYSE: DHR) Diagnostics platform. Cepheid is dedicated to improving healthcare by developing, manufacturing, and marketing accurate yet easy-to-use molecular systems and tests. By automating highly complex and time-consuming manual procedures, the company's solutions deliver a better way for institutions of any size to perform sophisticated molecular diagnostic testing for organisms and genetic-based diseases. Through its strong molecular biology capabilities, the company is focusing on those applications where accurate, rapid, and actionable test results are needed most, such as managing infectious diseases and cancer. For more information, visit http://www.cepheid.com

*Cepheid internal study based on 30 minute test results.

For Cepheid Media Inquiries:
Darwa Peterson
darwa.peterson@cepheid.com

Video - https://www.youtube.com/watch?v=J2NiuFc7gr4

DANAHER-Aktie komplett kostenlos handeln - auf Smartbroker.de
© 2020 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.